Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Vita Health topic
No spam. Unsubscribe anytime.
GIC staff outline Vita Health implementation and options to support members after GLP‑1 coverage change
Summary
Staff reported Vita enrollment, engagement metrics and a transition plan after the commission’s vote to eliminate GLP‑1 coverage for weight management; staff described eligibility exceptions, data limitations on comorbidities, and three options for July 1—wind down Vita, retain it for limited services, or keep full services with direct‑pay prescribing.
GIC staff updated commissioners on implementation metrics for the Vita Health weight‑management program and described options to support members after the commission’s prior vote to eliminate GLP‑1 coverage for weight‑loss indications effective July 1.
Implementation and engagement: Deputy Executive Director Erica Shabelli said Vita launched on schedule and, as of the prior week, had enrolled 11,049 GIC members. Staff reported engagement and customer service metrics exceed Vita’s expectations for similar clients; early net promoter score (NPS) was 22. Vita’s clinical protocols (labs, dietician interactions and clinician oversight) were functioning and staff noted rapid responsiveness to member feedback.
GLP‑1 transition details and exceptions: Staff reiterated the commission’s prior motion to eliminate GLP‑1 coverage for weight management starting July 1 but clarified that coverage will continue for diabetes and for three other clinical categories requiring prior authorization: metabolic dysfunction‑associated fatty liver disease (MAFLD/MASH) with moderate‑to‑advanced liver fibrosis; established cardiovascular disease with obesity or overweight to reduce major adverse cardiovascular event risk; and moderate‑to‑severe obstructive sleep apnea with obesity and specified comorbidities. Commissioners asked how many members in the transition population (members on GLP‑1s in the last 12 months, roughly 23,000) will meet qualifying exceptions; staff said granular comorbidity data are limited in prescribing feeds and they will request more detail from Vita and CVS.
Communications and options for July 1: Staff reviewed outreach cadence (emails, mailings, calls) and paused a scheduled transition reminder after the prior week’s vote to coordinate messaging. Three operational options under consideration were discussed: fully winding down Vita on July 1; maintaining Vita for continued prescribing via direct‑pay and other channels; or keeping Vita for behavioral and dietary support as an off‑ramp. Staff said weekly meetings with Vita and CVS will continue and that a final transition plan and communications would be shared with commissioners as soon as possible and prior to or shortly after the March 31 end of the transition grace period.
Member impacts and data requests: Commissioners emphasized the importance of granular demographic and drop‑off data to understand who is impacted. Staff committed to asking Vita and CVS for more detailed breakdowns about members who enroll, who drop off, and how many in the transition cohort have qualifying comorbidities. General counsel explained limitations on available prescribing‑side comorbidity data.
